Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 8/20 | 0.47 |
| ▸ | CES1 | P23141 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133928 | 0.81 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL6538767 | 0.80 | LMNA (0.42) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL5152357 | 0.80 | CES2 (0.43) | L3MBTL1CES2CES1ALDH1A1MAPT | |
| SCHEMBL5149263 | 0.80 | CES2 (0.43) | CES2CES1ALDH1A1MAPTHTT | |
| SCHEMBL286957 | 0.78 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL31728945 | 0.74 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL21395235 | 0.73 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| SCHEMBL2306577 | 0.73 | MAPT (0.55) | L3MBTL1ALDH1A1MAPTHTTRAB9A | |
| Benzil SCHEMBL4832229 | 0.69 | CES2 (0.88) | L3MBTL1CES2CES1ALDH1A1MAPT | |
| Benzil SCHEMBL27655380 | 0.69 | CES2 (0.88) | L3MBTL1CES2CES1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | L3MBTL1 1362/4885CES2 2400/4885CES1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.